{"id":347770,"date":"2025-08-25T12:54:57","date_gmt":"2025-08-25T12:54:57","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-ultragenyx-pharmaceutical\/"},"modified":"2025-08-25T12:54:57","modified_gmt":"2025-08-25T12:54:57","slug":"how-to-buy-ultragenyx-pharmaceutical","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/","title":{"rendered":"Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ultragenyx Pharmaceutical Inc. (RARE) Hisse Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334090,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-347770","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ultragenyx Pharmaceutical Inc. (RARE) Hisse Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ultragenyx Pharmaceutical Inc. (RARE) Hisse Yat\u0131r\u0131m\u0131"},"description":"Ultragenyx Pharmaceutical Inc. (RARE) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin; g\u00fcncel fiyat analizi, ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ve bu umut vadeden biyoteknoloji \u015firketi hakk\u0131nda uzman g\u00f6r\u00fc\u015fleri dahil.","description_source":{"label":"Description","type":"textarea","formatted_value":"Ultragenyx Pharmaceutical Inc. (RARE) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin; g\u00fcncel fiyat analizi, ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ve bu umut vadeden biyoteknoloji \u015firketi hakk\u0131nda uzman g\u00f6r\u00fc\u015fleri dahil."},"intro":"Keskin gen terapisine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Ultragenyx Pharmaceutical Inc. (RARE), nadir hastal\u0131k tedavisi geli\u015ftirme alan\u0131nda heyecan verici bir s\u0131n\u0131r\u0131 temsil ediyor. Bu yenilik\u00e7i biyoteknoloji \u015firketi, geli\u015fmi\u015f \u00fcr\u00fcn hatt\u0131 ve son d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131yla dikkat \u00e7ekiyor. RARE hisselerinin neden dikkatinizi hak etti\u011fini ve bu t\u0131bbi devrimin bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Keskin gen terapisine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Ultragenyx Pharmaceutical Inc. (RARE), nadir hastal\u0131k tedavisi geli\u015ftirme alan\u0131nda heyecan verici bir s\u0131n\u0131r\u0131 temsil ediyor. Bu yenilik\u00e7i biyoteknoloji \u015firketi, geli\u015fmi\u015f \u00fcr\u00fcn hatt\u0131 ve son d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131yla dikkat \u00e7ekiyor. RARE hisselerinin neden dikkatinizi hak etti\u011fini ve bu t\u0131bbi devrimin bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Performans\u0131 ve Piyasa Konumu<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, Ultragenyx Pharmaceutical Inc. (RARE) hisseleri <strong>29,78 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. \u015eirket, son alt\u0131 ayda \u00f6nemli dalgalanmalar ya\u015fad\u0131; fiyatlar Haziran sonlar\u0131nda 36,52 $ civar\u0131nda zirve yaparken, \u015fu anki seviyeler yakla\u015f\u0131k %20 d\u00fc\u015f\u00fc\u015f\u00fc temsil ediyor.<\/p> <p><strong>Takviminize not edin: 4 Kas\u0131m 2025<\/strong>, RARE yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kesinlikle kritik bir tarih. \u015eirketin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn bu. Tarihsel olarak, bu a\u00e7\u0131klamalar \u00f6nemli fiyat hareketlerine yol a\u00e7m\u0131\u015ft\u0131r.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 RARE Hisselerini Nas\u0131l Etkiler?<\/h3> <p>Son tarihlere bak\u0131ld\u0131\u011f\u0131nda, net bir desen g\u00f6r\u00fclebilir:<\/p> <ul> <li><strong>5 A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 a\u00e7\u0131kland\u0131; hisse ba\u015f\u0131na zarar (EPS) -1,17 $ (tahminleri 0,10 $ a\u015ft\u0131) ve gelir 166,50 milyon $ (y\u0131ll\u0131k %13,2 art\u0131\u015f). Beklentileri a\u015fmas\u0131na ra\u011fmen, hisse fiyat\u0131 kazan\u00e7 \u00f6ncesi yakla\u015f\u0131k 32 $ seviyesinden \u015fu anki 29,78 $ aral\u0131\u011f\u0131na d\u00fc\u015ft\u00fc.<\/li> <li><strong>May\u0131s 2025<\/strong>: 1. \u00e7eyrek kazan\u00e7lar\u0131 139 milyon $ gelir (y\u00fczde 28 b\u00fcy\u00fcme) g\u00f6sterdi ancak d\u00fczenleyici endi\u015feler nedeniyle hisse volatil kald\u0131.<\/li> <\/ul> <p>Bu desen, Ultragenyx'in gelir beklentilerini s\u00fcrekli a\u015fmas\u0131na ra\u011fmen, yat\u0131r\u0131mc\u0131lar\u0131n k\u00e2rl\u0131l\u0131k yolunda ve d\u00fczenleyici engeller konusunda temkinli oldu\u011funu g\u00f6steriyor.<\/p> <h3>6 Ayl\u0131k Fiyat Yolculu\u011fu Analizi<\/h3> <p>\u015eubat'tan A\u011fustos 2025'e kadar RARE hisseleri olduk\u00e7a dalgal\u0131 bir seyir izledi:<\/p> <p><strong>\u015eubat 2025<\/strong>: Yat\u0131r\u0131mc\u0131lar 2024 4. \u00e7eyrek sonu\u00e7lar\u0131n\u0131 beklerken 32-35 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<br> <strong>Mart 2025<\/strong>: Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fc endi\u015feleri nedeniyle 28-30 $ aral\u0131\u011f\u0131na d\u00fc\u015ft\u00fc<br> <strong>May\u0131s 2025<\/strong>: G\u00fc\u00e7l\u00fc 1. \u00e7eyrek gelir b\u00fcy\u00fcmesi (%28) sonras\u0131 34-36 $ aral\u0131\u011f\u0131na toparland\u0131<br> <strong>Haziran 2025<\/strong>: \u00dcr\u00fcn hatt\u0131 ilerlemesiyle ilgili iyimserlikle 36,52 $ civar\u0131nda zirve yapt\u0131<br> <strong>Temmuz 2025<\/strong>: UX111 i\u00e7in FDA Tam Yan\u0131t Mektubu sonras\u0131 29-31 $ aral\u0131\u011f\u0131na geriledi<br> <strong>A\u011fustos 2025<\/strong>: Pozitif 2. \u00e7eyrek kazan\u00e7lar\u0131 a\u015fmas\u0131na ra\u011fmen 29-30 $ civar\u0131nda istikrar sa\u011flad\u0131<\/p> <p>Genel e\u011filim, hem b\u00fcy\u00fck f\u0131rsatlarla hem de \u00f6nemli zorluklarla kar\u015f\u0131 kar\u015f\u0131ya olan bir \u015firketi g\u00f6steriyor; bu da deneyimli yat\u0131r\u0131mc\u0131lar\u0131n yararlanabilece\u011fi volatiliteyi yarat\u0131yor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Kapsaml\u0131 analist ara\u015ft\u0131rmalar\u0131 ve mevcut \u00fcr\u00fcn hatt\u0131 geli\u015fmelerine dayanarak, uzmanlar\u0131n projeksiyonlar\u0131 \u015funlard\u0131r:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: 48-55 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %60-85 art\u0131\u015f) - <strong>AL<\/strong> tavsiyesi<br> Beklenen 3. ve 4. \u00e7eyrek gelir b\u00fcy\u00fcmesi ile potansiyel d\u00fczenleyici ilerlemeler bu iyimser g\u00f6r\u00fcn\u00fcm\u00fc destekliyor.<\/p> <p><strong>2026 Tahmini<\/strong>: 65-75 $ aral\u0131\u011f\u0131<br> Bir\u00e7ok analist, yeni terapilerin onay almas\u0131 ve gelir katk\u0131s\u0131n\u0131n anlaml\u0131 \u015fekilde ba\u015flamas\u0131yla 2026'da \"b\u00fcy\u00fck gelir d\u00f6n\u00fc\u015f\u00fcm\u00fc\" bekliyor.<\/p> <p><strong>2028 Projeksiyonu<\/strong>: 85-100+ $ aral\u0131\u011f\u0131<br> William Blair analizine g\u00f6re 2028 sonuna kadar onaylanmas\u0131 beklenen alt\u0131 ek terap\u00f6tik ile gelir taban\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde geni\u015fleyebilir.<\/p> <p><strong>2030 Vizyonu<\/strong>: 120-150+ $ potansiyel<br> Uzun vadeli analistler, setrusumab gibi blockbuster \u00fcr\u00fcnlerin 2037'ye kadar 2,4 milyar $ zirve gelir yaratabilece\u011fini ve Ultragenyx'in bu de\u011ferin yakla\u015f\u0131k 1,4 milyar $'\u0131n\u0131 yakalayaca\u011f\u0131n\u0131 \u00f6ng\u00f6r\u00fcyor.<\/p> <p>21 arac\u0131 kurumun ortalama tavsiyesi 1,7 (\"\u00dcst\u00fcn Performans\" durumu) olup, fiyat hedefleri 39 $ ile 136 $ aras\u0131nda de\u011fi\u015fmektedir ve genel g\u00f6r\u00fc\u015f olduk\u00e7a pozitiftir.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>D\u00fczenleyici Zorluklar<\/strong>: Temmuz 2025'te UX111 i\u00e7in FDA Tam Yan\u0131t Mektubu, di\u011fer \u00fcr\u00fcn hatt\u0131 \u00fcr\u00fcnlerini etkileyebilecek \u00fcretim ve kalite kontrol sorunlar\u0131n\u0131 vurgulad\u0131.<\/li> <li><strong>Mali S\u00fcrd\u00fcr\u00fclebilirlik<\/strong>: 2025 1. \u00e7eyre\u011finde %28 gelir art\u0131\u015f\u0131na ra\u011fmen, \u015firket 2024 y\u0131l\u0131nda 569 milyon $ net zarar bildirdi. K\u00e2rl\u0131l\u0131\u011fa ge\u00e7i\u015f yolu belirsizli\u011fini koruyor.<\/li> <li><strong>Y\u00fcksek Volatilite<\/strong>: G\u00fcnl\u00fck ortalama %4,31 fiyat dalgalanmas\u0131 ile RARE, riskten ka\u00e7\u0131nan yat\u0131r\u0131mc\u0131lar i\u00e7in uygun de\u011fil. 52 haftal\u0131k fiyat aral\u0131\u011f\u0131 25,81 $ ile 60,37 $ aras\u0131nda a\u015f\u0131r\u0131 volatiliteyi g\u00f6steriyor.<\/li> <li><strong>\u00dcr\u00fcn Hatt\u0131na Ba\u011f\u0131ml\u0131l\u0131k<\/strong>: \u015eirketin de\u011feri, geli\u015ftirilmekte olan birden fazla gen terapisinin ba\u015far\u0131l\u0131 d\u00fczenleyici onaylar\u0131na b\u00fcy\u00fck \u00f6l\u00e7\u00fcde ba\u011fl\u0131d\u0131r.<\/li> <\/ul> <h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>G\u00fc\u00e7l\u00fc Gelir B\u00fcy\u00fcmesi<\/strong>: 2025 2. \u00e7eyrek geliri 166,50 milyon $ ile y\u0131ll\u0131k %13,2 art\u0131\u015f g\u00f6sterdi ve analist beklentilerini a\u015ft\u0131.<\/li> <li><strong>DTX401 BLA \u0130lerlemesi<\/strong>: 18 A\u011fustos 2025'te DTX401 gen terapisi i\u00e7in ABD FDA'ya kademeli Biyolojik Lisans Ba\u015fvurusu (BLA) ba\u015flat\u0131lmas\u0131 \u00f6nemli bir d\u00fczenleyici d\u00f6n\u00fcm noktas\u0131d\u0131r (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/18\/3134959\/0\/en\/Ultragenyx-Initiates-Rolling-Submission-of-Biologics-License-Application-BLA-to-U-S-FDA-for-DTX401-AAV-Gene-Therapy-for-the-Treatment-of-Glycogen-Storage-Disease-Type-Ia-GSDIa.html\">Resmi Duyuru<\/a>).<\/li> <li><strong>Analist G\u00fcveni<\/strong>: 21 analistin 20'si RARE i\u00e7in Al veya G\u00fc\u00e7l\u00fc Al derecesi veriyor ve ortalama fiyat hedefleri %190'dan fazla y\u00fckseli\u015f potansiyeli g\u00f6steriyor.<\/li> <li><strong>Piyasa Konumu<\/strong>: Ultragenyx, \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131 olan nadir hastal\u0131klar\u0131 hedefleyerek onay sonras\u0131 premium fiyatland\u0131rma ve h\u0131zl\u0131 benimseme potansiyeli yarat\u0131yor.<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2> <p>Mevcut durumu analizime dayanarak, i\u015fte tavsiyelerim:<\/p> <ul> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Volatilite g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, toplam portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazla olmayan bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n. Bu, yukar\u0131 y\u00f6nl\u00fc hareketlerden faydalan\u0131rken a\u015fa\u011f\u0131 y\u00f6nl\u00fc riski s\u0131n\u0131rlar.<\/li> <li><strong>Ortalama maliyet y\u00f6ntemi kullan\u0131n<\/strong>: T\u00fcm hisseleri tek seferde almak yerine, volatilite i\u00e7inde giri\u015f fiyatlar\u0131n\u0131 dengelemek i\u00e7in birka\u00e7 hafta boyunca al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn.<\/li> <li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong>: 27,20 $ g\u00fc\u00e7l\u00fc destek seviyesi iken, 32 $ \u00fczerindeki k\u0131r\u0131lmalar yenilenen y\u00fckseli\u015f momentumu sinyali olabilir.<\/li> <li><strong>Bilgili kal\u0131n<\/strong>: 4 Kas\u0131m'daki 3. \u00e7eyrek kazan\u00e7 tarihini i\u015faretleyin ve 2025 4. \u00e7eyrekte beklenen DTX401 BLA tamamlanmas\u0131 ile ilgili FDA g\u00fcncellemelerini takip edin.<\/li> <li><strong>Esprili deneyimli tavsiyesi<\/strong>: \"RARE gibi biyoteknoloji hisseleriyle ticaret yapmak gen terapisi yapmak gibidir - sab\u0131rl\u0131 olmal\u0131, volatiliteye dayanmal\u0131 ve bug\u00fcn\u00fcn ara\u015ft\u0131rmas\u0131n\u0131n yar\u0131n\u0131n mucizesi olaca\u011f\u0131na inanmal\u0131s\u0131n\u0131z. Portf\u00f6y DNA'n\u0131z\u0131 uygun risk y\u00f6netimi olmadan kesmeye \u00e7al\u0131\u015fmay\u0131n!\"<\/li> <\/ul> <h2>\u2705 Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ listeleri ve rekabet\u00e7i komisyon oranlar\u0131 sunan bir arac\u0131 kurum se\u00e7in<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td><td>RARE'in volatilitesi g\u00f6z \u00f6n\u00fcne al\u0131narak riske atmaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>G\u00fcncel fiyat\u0131 ara\u015ft\u0131r\u0131n<\/td><td>Ger\u00e7ek zamanl\u0131 fiyatlar\u0131 kontrol edin - RARE NASDAQ'da \"RARE\" sembol\u00fc ile i\u015flem g\u00f6r\u00fcr<\/td><\/tr> <tr><td>4<\/td><td>Emrinizi verin<\/td><td>Piyasa emirleri yerine giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 izleyin<\/td><td>Hisse haberlerine duyarl\u0131l\u0131\u011f\u0131 nedeniyle kazan\u00e7 tarihleri ve \u00f6nemli fiyat seviyeleri i\u00e7in uyar\u0131lar kurun<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2> <p>Ultragenyx Pharmaceutical ile yat\u0131r\u0131m yolculu\u011funa ba\u015flamak isteyenler i\u00e7in Pocket Option, yeni ba\u015flayan yat\u0131r\u0131mc\u0131lar i\u00e7in mant\u0131kl\u0131 birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Eri\u015filebilirlik<\/strong>: Sadece 5 $ minimum depozito ile stratejileri test edebilir ve \u00f6nemli finansal taahh\u00fct olmadan deneyim kazanabilirsiniz.<\/li> <li><strong>H\u0131zl\u0131 S\u00fcre\u00e7<\/strong>: Tek bir belge ile 1 dakikal\u0131k KYC do\u011frulamas\u0131 sayesinde hesap olu\u015fturduktan hemen sonra i\u015flem yapmaya ba\u015flayabilirsiniz.<\/li> <li><strong>Esnek Se\u00e7enekler<\/strong>: Kripto, e-c\u00fczdan veya geleneksel bankac\u0131l\u0131k se\u00e7enekleri olsun, 100'den fazla para \u00e7ekme y\u00f6ntemi sunar.<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve d\u00fc\u015f\u00fck giri\u015f engelleri, RARE gibi heyecan verici biyoteknoloji hisselerine maruz kalmak isteyen ancak geleneksel arac\u0131 hesaplar\u0131n\u0131n karma\u015f\u0131kl\u0131\u011f\u0131ndan ka\u00e7\u0131nmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel bir se\u00e7imdir.<\/p> <h2>\ud83c\udf0d 2025'te Ultragenyx: Nadir Hastal\u0131k Tedavisinde \u00d6nc\u00fc<\/h2> <p>Ultragenyx Pharmaceutical, nadir ve ultra-nadir genetik hastal\u0131klar i\u00e7in tedaviler geli\u015ftirmede genetik t\u0131bb\u0131n \u00f6n saflar\u0131nda yer almaktad\u0131r. \u015eirketin mevcut ticari \u00fcr\u00fcnleri aras\u0131nda, sadece 2025 1. \u00e7eyre\u011finde 103 milyon $ gelir getiren X'e ba\u011fl\u0131 hipofosfatemi i\u00e7in Crysvita\u00ae bulunmaktad\u0131r.<\/p> <p>\u015eirketin \u00fcr\u00fcn hatt\u0131, Sanfilippo sendromu, Angelman sendromu ve glikojen depo hastal\u0131\u011f\u0131 tip Ia gibi durumlar\u0131 hedefleyen birden fazla ara\u015ft\u0131rma a\u015famas\u0131ndaki terapileri i\u00e7erir. Yakla\u015f\u0131mlar\u0131, k\u00fc\u00e7\u00fck hasta pop\u00fclasyonlar\u0131n\u0131 etkileyen ancak \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131 temsil eden durumlara derin bilimsel uzmanl\u0131k ve \u015fefkatli odaklanmay\u0131 birle\u015ftirir.<\/p> <p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Ultragenyx, klinik deneylerde DTX401 ile tedavi edilen hastalar\u0131n m\u0131s\u0131r ni\u015fastas\u0131 gereksinimlerinde %60-64 gibi \u00f6nemli azalmalar ya\u015fad\u0131\u011f\u0131n\u0131 ve baz\u0131lar\u0131n\u0131n y\u0131llard\u0131r ilk kez kesintisiz bir gece uykusunun tad\u0131n\u0131 \u00e7\u0131karabildi\u011fini duyurdu - glikojen depo hastal\u0131\u011f\u0131 ya\u015fayan insanlar i\u00e7in basit ama hayat de\u011fi\u015ftiren bir sonu\u00e7.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Performans\u0131 ve Piyasa Konumu<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, Ultragenyx Pharmaceutical Inc. (RARE) hisseleri <strong>29,78 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. \u015eirket, son alt\u0131 ayda \u00f6nemli dalgalanmalar ya\u015fad\u0131; fiyatlar Haziran sonlar\u0131nda 36,52 $ civar\u0131nda zirve yaparken, \u015fu anki seviyeler yakla\u015f\u0131k %20 d\u00fc\u015f\u00fc\u015f\u00fc temsil ediyor.<\/p>\n<p><strong>Takviminize not edin: 4 Kas\u0131m 2025<\/strong>, RARE yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kesinlikle kritik bir tarih. \u015eirketin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn bu. Tarihsel olarak, bu a\u00e7\u0131klamalar \u00f6nemli fiyat hareketlerine yol a\u00e7m\u0131\u015ft\u0131r.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 RARE Hisselerini Nas\u0131l Etkiler?<\/h3>\n<p>Son tarihlere bak\u0131ld\u0131\u011f\u0131nda, net bir desen g\u00f6r\u00fclebilir:<\/p>\n<ul>\n<li><strong>5 A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 a\u00e7\u0131kland\u0131; hisse ba\u015f\u0131na zarar (EPS) -1,17 $ (tahminleri 0,10 $ a\u015ft\u0131) ve gelir 166,50 milyon $ (y\u0131ll\u0131k %13,2 art\u0131\u015f). Beklentileri a\u015fmas\u0131na ra\u011fmen, hisse fiyat\u0131 kazan\u00e7 \u00f6ncesi yakla\u015f\u0131k 32 $ seviyesinden \u015fu anki 29,78 $ aral\u0131\u011f\u0131na d\u00fc\u015ft\u00fc.<\/li>\n<li><strong>May\u0131s 2025<\/strong>: 1. \u00e7eyrek kazan\u00e7lar\u0131 139 milyon $ gelir (y\u00fczde 28 b\u00fcy\u00fcme) g\u00f6sterdi ancak d\u00fczenleyici endi\u015feler nedeniyle hisse volatil kald\u0131.<\/li>\n<\/ul>\n<p>Bu desen, Ultragenyx&#8217;in gelir beklentilerini s\u00fcrekli a\u015fmas\u0131na ra\u011fmen, yat\u0131r\u0131mc\u0131lar\u0131n k\u00e2rl\u0131l\u0131k yolunda ve d\u00fczenleyici engeller konusunda temkinli oldu\u011funu g\u00f6steriyor.<\/p>\n<h3>6 Ayl\u0131k Fiyat Yolculu\u011fu Analizi<\/h3>\n<p>\u015eubat&#8217;tan A\u011fustos 2025&#8217;e kadar RARE hisseleri olduk\u00e7a dalgal\u0131 bir seyir izledi:<\/p>\n<p><strong>\u015eubat 2025<\/strong>: Yat\u0131r\u0131mc\u0131lar 2024 4. \u00e7eyrek sonu\u00e7lar\u0131n\u0131 beklerken 32-35 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<br \/> <strong>Mart 2025<\/strong>: Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fc endi\u015feleri nedeniyle 28-30 $ aral\u0131\u011f\u0131na d\u00fc\u015ft\u00fc<br \/> <strong>May\u0131s 2025<\/strong>: G\u00fc\u00e7l\u00fc 1. \u00e7eyrek gelir b\u00fcy\u00fcmesi (%28) sonras\u0131 34-36 $ aral\u0131\u011f\u0131na toparland\u0131<br \/> <strong>Haziran 2025<\/strong>: \u00dcr\u00fcn hatt\u0131 ilerlemesiyle ilgili iyimserlikle 36,52 $ civar\u0131nda zirve yapt\u0131<br \/> <strong>Temmuz 2025<\/strong>: UX111 i\u00e7in FDA Tam Yan\u0131t Mektubu sonras\u0131 29-31 $ aral\u0131\u011f\u0131na geriledi<br \/> <strong>A\u011fustos 2025<\/strong>: Pozitif 2. \u00e7eyrek kazan\u00e7lar\u0131 a\u015fmas\u0131na ra\u011fmen 29-30 $ civar\u0131nda istikrar sa\u011flad\u0131<\/p>\n<p>Genel e\u011filim, hem b\u00fcy\u00fck f\u0131rsatlarla hem de \u00f6nemli zorluklarla kar\u015f\u0131 kar\u015f\u0131ya olan bir \u015firketi g\u00f6steriyor; bu da deneyimli yat\u0131r\u0131mc\u0131lar\u0131n yararlanabilece\u011fi volatiliteyi yarat\u0131yor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Kapsaml\u0131 analist ara\u015ft\u0131rmalar\u0131 ve mevcut \u00fcr\u00fcn hatt\u0131 geli\u015fmelerine dayanarak, uzmanlar\u0131n projeksiyonlar\u0131 \u015funlard\u0131r:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 48-55 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %60-85 art\u0131\u015f) &#8211; <strong>AL<\/strong> tavsiyesi<br \/> Beklenen 3. ve 4. \u00e7eyrek gelir b\u00fcy\u00fcmesi ile potansiyel d\u00fczenleyici ilerlemeler bu iyimser g\u00f6r\u00fcn\u00fcm\u00fc destekliyor.<\/p>\n<p><strong>2026 Tahmini<\/strong>: 65-75 $ aral\u0131\u011f\u0131<br \/> Bir\u00e7ok analist, yeni terapilerin onay almas\u0131 ve gelir katk\u0131s\u0131n\u0131n anlaml\u0131 \u015fekilde ba\u015flamas\u0131yla 2026&#8217;da &#8220;b\u00fcy\u00fck gelir d\u00f6n\u00fc\u015f\u00fcm\u00fc&#8221; bekliyor.<\/p>\n<p><strong>2028 Projeksiyonu<\/strong>: 85-100+ $ aral\u0131\u011f\u0131<br \/> William Blair analizine g\u00f6re 2028 sonuna kadar onaylanmas\u0131 beklenen alt\u0131 ek terap\u00f6tik ile gelir taban\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde geni\u015fleyebilir.<\/p>\n<p><strong>2030 Vizyonu<\/strong>: 120-150+ $ potansiyel<br \/> Uzun vadeli analistler, setrusumab gibi blockbuster \u00fcr\u00fcnlerin 2037&#8217;ye kadar 2,4 milyar $ zirve gelir yaratabilece\u011fini ve Ultragenyx&#8217;in bu de\u011ferin yakla\u015f\u0131k 1,4 milyar $&#8217;\u0131n\u0131 yakalayaca\u011f\u0131n\u0131 \u00f6ng\u00f6r\u00fcyor.<\/p>\n<p>21 arac\u0131 kurumun ortalama tavsiyesi 1,7 (&#8220;\u00dcst\u00fcn Performans&#8221; durumu) olup, fiyat hedefleri 39 $ ile 136 $ aras\u0131nda de\u011fi\u015fmektedir ve genel g\u00f6r\u00fc\u015f olduk\u00e7a pozitiftir.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>D\u00fczenleyici Zorluklar<\/strong>: Temmuz 2025&#8217;te UX111 i\u00e7in FDA Tam Yan\u0131t Mektubu, di\u011fer \u00fcr\u00fcn hatt\u0131 \u00fcr\u00fcnlerini etkileyebilecek \u00fcretim ve kalite kontrol sorunlar\u0131n\u0131 vurgulad\u0131.<\/li>\n<li><strong>Mali S\u00fcrd\u00fcr\u00fclebilirlik<\/strong>: 2025 1. \u00e7eyre\u011finde %28 gelir art\u0131\u015f\u0131na ra\u011fmen, \u015firket 2024 y\u0131l\u0131nda 569 milyon $ net zarar bildirdi. K\u00e2rl\u0131l\u0131\u011fa ge\u00e7i\u015f yolu belirsizli\u011fini koruyor.<\/li>\n<li><strong>Y\u00fcksek Volatilite<\/strong>: G\u00fcnl\u00fck ortalama %4,31 fiyat dalgalanmas\u0131 ile RARE, riskten ka\u00e7\u0131nan yat\u0131r\u0131mc\u0131lar i\u00e7in uygun de\u011fil. 52 haftal\u0131k fiyat aral\u0131\u011f\u0131 25,81 $ ile 60,37 $ aras\u0131nda a\u015f\u0131r\u0131 volatiliteyi g\u00f6steriyor.<\/li>\n<li><strong>\u00dcr\u00fcn Hatt\u0131na Ba\u011f\u0131ml\u0131l\u0131k<\/strong>: \u015eirketin de\u011feri, geli\u015ftirilmekte olan birden fazla gen terapisinin ba\u015far\u0131l\u0131 d\u00fczenleyici onaylar\u0131na b\u00fcy\u00fck \u00f6l\u00e7\u00fcde ba\u011fl\u0131d\u0131r.<\/li>\n<\/ul>\n<h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>G\u00fc\u00e7l\u00fc Gelir B\u00fcy\u00fcmesi<\/strong>: 2025 2. \u00e7eyrek geliri 166,50 milyon $ ile y\u0131ll\u0131k %13,2 art\u0131\u015f g\u00f6sterdi ve analist beklentilerini a\u015ft\u0131.<\/li>\n<li><strong>DTX401 BLA \u0130lerlemesi<\/strong>: 18 A\u011fustos 2025&#8217;te DTX401 gen terapisi i\u00e7in ABD FDA&#8217;ya kademeli Biyolojik Lisans Ba\u015fvurusu (BLA) ba\u015flat\u0131lmas\u0131 \u00f6nemli bir d\u00fczenleyici d\u00f6n\u00fcm noktas\u0131d\u0131r (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/18\/3134959\/0\/en\/Ultragenyx-Initiates-Rolling-Submission-of-Biologics-License-Application-BLA-to-U-S-FDA-for-DTX401-AAV-Gene-Therapy-for-the-Treatment-of-Glycogen-Storage-Disease-Type-Ia-GSDIa.html\">Resmi Duyuru<\/a>).<\/li>\n<li><strong>Analist G\u00fcveni<\/strong>: 21 analistin 20&#8217;si RARE i\u00e7in Al veya G\u00fc\u00e7l\u00fc Al derecesi veriyor ve ortalama fiyat hedefleri %190&#8217;dan fazla y\u00fckseli\u015f potansiyeli g\u00f6steriyor.<\/li>\n<li><strong>Piyasa Konumu<\/strong>: Ultragenyx, \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131 olan nadir hastal\u0131klar\u0131 hedefleyerek onay sonras\u0131 premium fiyatland\u0131rma ve h\u0131zl\u0131 benimseme potansiyeli yarat\u0131yor.<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<p>Mevcut durumu analizime dayanarak, i\u015fte tavsiyelerim:<\/p>\n<ul>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Volatilite g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda, toplam portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazla olmayan bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n. Bu, yukar\u0131 y\u00f6nl\u00fc hareketlerden faydalan\u0131rken a\u015fa\u011f\u0131 y\u00f6nl\u00fc riski s\u0131n\u0131rlar.<\/li>\n<li><strong>Ortalama maliyet y\u00f6ntemi kullan\u0131n<\/strong>: T\u00fcm hisseleri tek seferde almak yerine, volatilite i\u00e7inde giri\u015f fiyatlar\u0131n\u0131 dengelemek i\u00e7in birka\u00e7 hafta boyunca al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn.<\/li>\n<li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong>: 27,20 $ g\u00fc\u00e7l\u00fc destek seviyesi iken, 32 $ \u00fczerindeki k\u0131r\u0131lmalar yenilenen y\u00fckseli\u015f momentumu sinyali olabilir.<\/li>\n<li><strong>Bilgili kal\u0131n<\/strong>: 4 Kas\u0131m&#8217;daki 3. \u00e7eyrek kazan\u00e7 tarihini i\u015faretleyin ve 2025 4. \u00e7eyrekte beklenen DTX401 BLA tamamlanmas\u0131 ile ilgili FDA g\u00fcncellemelerini takip edin.<\/li>\n<li><strong>Esprili deneyimli tavsiyesi<\/strong>: &#8220;RARE gibi biyoteknoloji hisseleriyle ticaret yapmak gen terapisi yapmak gibidir &#8211; sab\u0131rl\u0131 olmal\u0131, volatiliteye dayanmal\u0131 ve bug\u00fcn\u00fcn ara\u015ft\u0131rmas\u0131n\u0131n yar\u0131n\u0131n mucizesi olaca\u011f\u0131na inanmal\u0131s\u0131n\u0131z. Portf\u00f6y DNA&#8217;n\u0131z\u0131 uygun risk y\u00f6netimi olmadan kesmeye \u00e7al\u0131\u015fmay\u0131n!&#8221;<\/li>\n<\/ul>\n<h2>\u2705 Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ listeleri ve rekabet\u00e7i komisyon oranlar\u0131 sunan bir arac\u0131 kurum se\u00e7in<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td>\n<td>RARE&#8217;in volatilitesi g\u00f6z \u00f6n\u00fcne al\u0131narak riske atmaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>G\u00fcncel fiyat\u0131 ara\u015ft\u0131r\u0131n<\/td>\n<td>Ger\u00e7ek zamanl\u0131 fiyatlar\u0131 kontrol edin &#8211; RARE NASDAQ&#8217;da &#8220;RARE&#8221; sembol\u00fc ile i\u015flem g\u00f6r\u00fcr<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emrinizi verin<\/td>\n<td>Piyasa emirleri yerine giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 izleyin<\/td>\n<td>Hisse haberlerine duyarl\u0131l\u0131\u011f\u0131 nedeniyle kazan\u00e7 tarihleri ve \u00f6nemli fiyat seviyeleri i\u00e7in uyar\u0131lar kurun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2>\n<p>Ultragenyx Pharmaceutical ile yat\u0131r\u0131m yolculu\u011funa ba\u015flamak isteyenler i\u00e7in Pocket Option, yeni ba\u015flayan yat\u0131r\u0131mc\u0131lar i\u00e7in mant\u0131kl\u0131 birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Eri\u015filebilirlik<\/strong>: Sadece 5 $ minimum depozito ile stratejileri test edebilir ve \u00f6nemli finansal taahh\u00fct olmadan deneyim kazanabilirsiniz.<\/li>\n<li><strong>H\u0131zl\u0131 S\u00fcre\u00e7<\/strong>: Tek bir belge ile 1 dakikal\u0131k KYC do\u011frulamas\u0131 sayesinde hesap olu\u015fturduktan hemen sonra i\u015flem yapmaya ba\u015flayabilirsiniz.<\/li>\n<li><strong>Esnek Se\u00e7enekler<\/strong>: Kripto, e-c\u00fczdan veya geleneksel bankac\u0131l\u0131k se\u00e7enekleri olsun, 100&#8217;den fazla para \u00e7ekme y\u00f6ntemi sunar.<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve d\u00fc\u015f\u00fck giri\u015f engelleri, RARE gibi heyecan verici biyoteknoloji hisselerine maruz kalmak isteyen ancak geleneksel arac\u0131 hesaplar\u0131n\u0131n karma\u015f\u0131kl\u0131\u011f\u0131ndan ka\u00e7\u0131nmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel bir se\u00e7imdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Ultragenyx: Nadir Hastal\u0131k Tedavisinde \u00d6nc\u00fc<\/h2>\n<p>Ultragenyx Pharmaceutical, nadir ve ultra-nadir genetik hastal\u0131klar i\u00e7in tedaviler geli\u015ftirmede genetik t\u0131bb\u0131n \u00f6n saflar\u0131nda yer almaktad\u0131r. \u015eirketin mevcut ticari \u00fcr\u00fcnleri aras\u0131nda, sadece 2025 1. \u00e7eyre\u011finde 103 milyon $ gelir getiren X&#8217;e ba\u011fl\u0131 hipofosfatemi i\u00e7in Crysvita\u00ae bulunmaktad\u0131r.<\/p>\n<p>\u015eirketin \u00fcr\u00fcn hatt\u0131, Sanfilippo sendromu, Angelman sendromu ve glikojen depo hastal\u0131\u011f\u0131 tip Ia gibi durumlar\u0131 hedefleyen birden fazla ara\u015ft\u0131rma a\u015famas\u0131ndaki terapileri i\u00e7erir. Yakla\u015f\u0131mlar\u0131, k\u00fc\u00e7\u00fck hasta pop\u00fclasyonlar\u0131n\u0131 etkileyen ancak \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131 temsil eden durumlara derin bilimsel uzmanl\u0131k ve \u015fefkatli odaklanmay\u0131 birle\u015ftirir.<\/p>\n<p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Ultragenyx, klinik deneylerde DTX401 ile tedavi edilen hastalar\u0131n m\u0131s\u0131r ni\u015fastas\u0131 gereksinimlerinde %60-64 gibi \u00f6nemli azalmalar ya\u015fad\u0131\u011f\u0131n\u0131 ve baz\u0131lar\u0131n\u0131n y\u0131llard\u0131r ilk kez kesintisiz bir gece uykusunun tad\u0131n\u0131 \u00e7\u0131karabildi\u011fini duyurdu &#8211; glikojen depo hastal\u0131\u011f\u0131 ya\u015fayan insanlar i\u00e7in basit ama hayat de\u011fi\u015ftiren bir sonu\u00e7.<\/p>\n"},"faq":[{"question":"Ultragenyx Pharmaceutical Inc. (RARE) hisseleri nereden al\u0131nabilir?","answer":"RARE hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"RARE hisseleri almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ti\u011finiz arac\u0131 kuruma ba\u011fl\u0131d\u0131r. Pocket Option gibi platformlarda 5 $ gibi d\u00fc\u015f\u00fck depozito ile ba\u015flayabilirsiniz."},{"question":"RARE hisselerinin fiyat\u0131 ne kadar dalgalan\u0131yor?","answer":"RARE hisseleri y\u00fcksek volatiliteye sahiptir; g\u00fcnl\u00fck ortalama fiyat dalgalanmas\u0131 %4,31 civar\u0131ndad\u0131r ve 52 haftal\u0131k fiyat aral\u0131\u011f\u0131 25,81 $ ile 60,37 $ aras\u0131ndad\u0131r."},{"question":"RARE hisseleri i\u00e7in gelecekteki fiyat beklentileri nelerdir?","answer":"Analistlerin tahminlerine g\u00f6re 2025 sonunda 48-55 $, 2026'da 65-75 $, 2028'de 85-100+ $ ve 2030'da 120-150+ $ aral\u0131\u011f\u0131nda fiyatlar beklenmektedir."},{"question":"RARE hisselerine yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"D\u00fczenleyici riskler, mali s\u00fcrd\u00fcr\u00fclebilirlik, y\u00fcksek volatilite ve \u00fcr\u00fcn hatt\u0131 onaylar\u0131na ba\u011f\u0131ml\u0131l\u0131k gibi riskleri g\u00f6z \u00f6n\u00fcnde bulundurun. Ayr\u0131ca k\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131p fiyat uyar\u0131lar\u0131 kurmak ve g\u00fcncel haberleri takip etmek \u00f6nemlidir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Ultragenyx Pharmaceutical Inc. (RARE) hisseleri nereden al\u0131nabilir?","answer":"RARE hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"RARE hisseleri almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ti\u011finiz arac\u0131 kuruma ba\u011fl\u0131d\u0131r. Pocket Option gibi platformlarda 5 $ gibi d\u00fc\u015f\u00fck depozito ile ba\u015flayabilirsiniz."},{"question":"RARE hisselerinin fiyat\u0131 ne kadar dalgalan\u0131yor?","answer":"RARE hisseleri y\u00fcksek volatiliteye sahiptir; g\u00fcnl\u00fck ortalama fiyat dalgalanmas\u0131 %4,31 civar\u0131ndad\u0131r ve 52 haftal\u0131k fiyat aral\u0131\u011f\u0131 25,81 $ ile 60,37 $ aras\u0131ndad\u0131r."},{"question":"RARE hisseleri i\u00e7in gelecekteki fiyat beklentileri nelerdir?","answer":"Analistlerin tahminlerine g\u00f6re 2025 sonunda 48-55 $, 2026'da 65-75 $, 2028'de 85-100+ $ ve 2030'da 120-150+ $ aral\u0131\u011f\u0131nda fiyatlar beklenmektedir."},{"question":"RARE hisselerine yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"D\u00fczenleyici riskler, mali s\u00fcrd\u00fcr\u00fclebilirlik, y\u00fcksek volatilite ve \u00fcr\u00fcn hatt\u0131 onaylar\u0131na ba\u011f\u0131ml\u0131l\u0131k gibi riskleri g\u00f6z \u00f6n\u00fcnde bulundurun. Ayr\u0131ca k\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131p fiyat uyar\u0131lar\u0131 kurmak ve g\u00fcncel haberleri takip etmek \u00f6nemlidir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ultragenyx Pharmaceutical Inc. (RARE) Hisse Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ultragenyx Pharmaceutical Inc. (RARE) Hisse Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T12:54:57+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ultragenyx Pharmaceutical Inc. (RARE) Hisse Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T12:54:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/\"},\"wordCount\":20,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/\",\"name\":\"Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ultragenyx Pharmaceutical Inc. (RARE) Hisse Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"datePublished\":\"2025-08-25T12:54:57+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ultragenyx Pharmaceutical Inc. (RARE) Hisse Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ultragenyx Pharmaceutical Inc. (RARE) Hisse Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/","og_locale":"tr_TR","og_type":"article","og_title":"Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ultragenyx Pharmaceutical Inc. (RARE) Hisse Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T12:54:57+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ultragenyx Pharmaceutical Inc. (RARE) Hisse Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T12:54:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/"},"wordCount":20,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/","name":"Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ultragenyx Pharmaceutical Inc. (RARE) Hisse Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","datePublished":"2025-08-25T12:54:57+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Ultragenyx Pharmaceutical Inc. (RARE) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ultragenyx Pharmaceutical Inc. (RARE) Hisse Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":347771,"slug":"how-to-buy-ultragenyx-pharmaceutical","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Ultragenyx Pharmaceutical Inc. (RARE) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Ultragenyx Pharmaceutical Inc. (RARE)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/"},"pt_AA":{"locale":"pt_AA","id":347775,"slug":"how-to-buy-ultragenyx-pharmaceutical","post_title":"Como comprar a\u00e7\u00f5es da Ultragenyx Pharmaceutical Inc. (RARE) - Investimento em a\u00e7\u00f5es da Ultragenyx Pharmaceutical Inc. (RARE)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-ultragenyx-pharmaceutical\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/347770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=347770"}],"version-history":[{"count":1,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/347770\/revisions"}],"predecessor-version":[{"id":347772,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/347770\/revisions\/347772"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334090"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=347770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=347770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=347770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}